Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | LIG1 | P18858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918796 | 0.80 | F2 (0.54) | DAOTSHRMEN1RAB9AKMT2A | |
| SCHEMBL217943 | 0.80 | LMNA (0.48) | DAOTSHRRAB9AKDM4EALDH1A1 | |
| SCHEMBL1372080 | 0.79 | NPSR1 (0.53) | DAOTSHRRAB9AKMT2AKDM4E | |
| SCHEMBL17212949 | 0.78 | DAO (0.42) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL1889191 | 0.78 | DAO (0.47) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL4959835 | 0.77 | DAO (0.36) | DAOTSHRPKMLIG1KMT2A | |
| SCHEMBL70493 | 0.77 | DAO (0.67) | DAOPKMLIG1MEN1POLB | |
| Hydrochloric Acid SCHEMBL1979156 | 0.75 | DAO (0.64) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL19987844 | 0.75 | DAO (0.64) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL11598753 | 0.75 | DAO (0.64) | DAOPKMLIG1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 382 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025231161-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | AI BIO DISCOVERY LLC (US) | 2025-11-06 | — | — | WO | claimed |
| US-20250332181-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | AI BIO DISCOVERY LLC (US) | 2025-10-30 | — | — | US | claimed |
| WO-2025231161-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | AI BIO DISCOVERY LLC (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250332181-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | AI BIO DISCOVERY LLC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-06-05 | — | — | US | disclosed |
| EP-4452918-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240317707-A1 | COVALENT AND NON-COVALENT INHIBITORS OF CORONAVIRUS PAPAIN-LIKE PROTEASE | U. S. DEPARTMENT OF ENERGY | 2024-09-26 | — | — | US | disclosed |
| US-20240166598-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-23 | — | — | US | disclosed |
| CN-115260211-B | Thiophene condensed ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2023246876-A1 | MEDICAL USE OF FORMAMIDE DERIVATIVES, FORMAMIDE DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 上海科技大学 | 2023-12-28 | — | — | WO | disclosed |
| CN-117285520-A | Medical use of carboxamide derivative, carboxamide derivative and pharmaceutical composition containing carboxamide derivative | 上海科技大学 | 2023-12-26 | — | — | CN | disclosed |
| EP-1525199-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS | Argenta Discovery Limited (GB) | 2005-04-27 | — | — | EP | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005014588-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS HAVING HISTONE DEACETYLASE ACTIVITY | ARGENTA DISCOVERY LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014588-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS HAVING HISTONE DEACETYLASE ACTIVITY | ARGENTA DISCOVERY LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004072025-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004013130-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | DAO 235/4885TSHR 3707/4885PKM 708/4885 |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | DAO 2316/4885TSHR 565/4885PKM 1838/4885 |
| US-20240166598-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME | SARS1, ACE, PLPBP | DAO 125/4885TSHR 4501/4885PKM 1496/4885 |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | DAO 344/4885TSHR 3373/4885PKM 381/4885 |
| US-20250332181-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | CMBL, EBPL, BPGM | DAO 18/4885TSHR 3166/4885PKM 2528/4885 |
| US-20240317707-A1 | COVALENT AND NON-COVALENT INHIBITORS OF CORONAVIRUS PAPAIN-LIKE PROTEASE | HPN, CTRL, CPN1 | DAO 634/4885TSHR 245/4885PKM 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.